


Appln No.: 09/674,191
 Amendment Dated: July 13, 2005
 Reply to Examiner's Amendment of June 3, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A compound of the formula



wherein:

R^1 is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

Y is a member selected from the group consisting of hydrogen, optionally substituted optionally-substituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl and optionally-substituted heteroaryl;

X is a member selected from the group consisting of optionally-substituted amino, oxygen, sulfur and a carbon single bond;

R_2 is a member selected from the group consisting of $C_6 - C_{26}$ alkyl, $C_6 - C_{26}$ alkenyl, dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-diacyl-sn-glycero-3-phosphoethenyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl;

R_3 is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

n is greater than 1; and

i is greater than 1.

2. (previously presented) A compound in accordance with claim 1, wherein:

Y is a member selected from the group consisting of hydrogen, optionally-substituted C_1-C_4 alkyl, optionally-substituted C_5-C_6 cycloalkyl and optionally-substituted phenyl;

Appln No.: 09/674,191

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

X is a member selected from the group consisting of optionally-substituted amino, oxygen and sulfur;

R² is a member selected from the group consisting of C₆-C₂₆ alkyl and C₆-C₂₆ alkenyl; n and i, added together, have a sum of 40 to 250.

3. (previously presented) A compound in accordance with claim 1, wherein:

Y is a member selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally substituted C5-C6 cycloalkyl and optionally substituted phenyl;

X is optionally-substituted amino;

R² is a member selected from the group consisting of C₆-C₂₆ alkyl and C₆-C₂₆ alkenyl; n and i added together have a sum of 40 to 250.

4. (previously presented) A compound in accordance with claim 1, wherein:

Y is a member selected from the group consisting of hydrogen, optionally substituted C1-C4 alkyl, optionally-substituted C5-C6 cycloalkyl and optionally-substituted phenyl;

X is a carbon single bond;

R² is a member selected from the group consisting of dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-diacyl-sn-glycero-3-phosphoethylenyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl;

n and i added together have a sum of 40 to 250.

5. (previously presented) A compound in accordance with claim 1, wherein:


Y is a member selected from the group consisting of hydrogen, optionally substituted C₁-C₄ alkyl, optionally-substituted C5-C6 cycloalkyl and optionally-substituted phenyl;

X is a carbon single bond;

R² is a member selected from the group consisting of dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl; and n and i, added together, have a sum of 40 to 250.

6. (original) A compound in accordance with claim 1, wherein:

R³ is a ligand, said ligand being a member selected from the group consisting of a lipid, polyethylene glycol and a compound of the formula



Appln No.: 09/674,191
Amendment Dated: July 13, 2005
Reply to Examiner's Amendment of June 3, 2005

wherein:

R^4 is a member selected from the group consisting of hydrogen and alkyl;
 R is a member of the group selected from hydrogen, optionally substituted alkyl, optionally-substituted aryl and a side chain of an amino acid;
 R^6 is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, mercapto, hydrazino, amino and NR^7R^8 , wherein R^7 and R^8 are independently hydrogen or alkyl;
 z is 4 to 80; m is 2 to 6;
 p is 1 to 4; and q is 0 or 1.

7. (original) A compound in accordance with claim 1, wherein:

R is a member selected from the group consisting of C_{10} - C_{18} alkyl and C_{10} - C_{18} alkenyl.

8. (original) A compound in accordance with claim 1, wherein:

R^2 is a member selected from the group consisting of dialkylglycerolyl and dialkenylglycerolyl, wherein said dialkyl groups are C_{10} - C_{18} dialkyl and said dialkenyl groups are C_{10} - C_{18} dialkenyl.

9. (original) A compound in accordance with claim 1, wherein:

R^2 is a member selected from the group consisting of diacylglycerolyl and 1,2-diacyl-sn-glycero-3-phosphoethenyl, wherein said diacyl groups are C_{10} - C_{18} diacyl.

10. (original) A compound in accordance with claim 1, wherein:

R^2 is a member selected from the group consisting of C_{10} alkyl and C_{10} alkenyl.

11. (original) A compound in accordance with claim 1, wherein:


R^2 is a member selected from the group consisting of dialkylglycerolyl and dialkenylglycerolyl, wherein said dialkyl groups are C_{10} dialkyl and said dialkenyl groups are C_{10} dialkenyl.

12. (original) A compound in accordance with claim 1, wherein:

R^2 is a member selected from the group consisting of diacylglycerolyl and 1,2-diacyl-sn-glycero-3-phosphoethenyl, wherein said diacyl groups are C_{10} acyl.

13. (previously presented) A pH-sensitive liposome, said liposome comprising a lipid and a compound of the formula

Appln No.: 09/674,191
 Amendment Dated: July 13, 2005
 Reply to Examiner's Amendment of June 3, 2005



wherein:

R^1 is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

Y is a member selected from the group consisting of hydrogen, optionallysubstituted alkyl, optionally-substituted cycloalkyl, optionally-substituted aryl and optionally-substituted heteroaryl;

X is a member selected from the group consisting of optionally-substituted amino, oxygen, sulfur a carbon single bond;

R_2 is a member selected from the group consisting of $\text{C}_6 - \text{C}_{26}$ alkyl, $\text{C}_6 - \text{C}_{26}$ alkenyl, dialkylglycerolyl, dialkenylglycerolyl, diacylglycerolyl, 1,2-diacyl-sn-glycero-3-phosphoethenyl, 1,2-dialkoxy-3-aminopropanyl and 1,2-diacyloxy-3-aminopropanyl;

R^3 is a member selected from the group consisting of hydrogen, hydroxyl, amino, optionally-substituted alkyl and a ligand;

n is greater than 1; and

i is greater than 1.

14. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome is fusogenic.

15. (previously presented) A pH-sensitive liposome in accordance with claim 13 wherein said lipid is a member selected from the group consisting of phosphoglycerides, sphingolipids, phosphatidylcholine, phosphatidylethanolamine, lipolyamines, and cholesterol-based lipids.

16. (original) A pH-sensitive liposome in accordance with claim 15 wherein said lipid is a phosphatidylcholine.

17. (original) A pH-sensitive liposome in accordance with claim 16 wherein said phosphatidylcholine lipid is a member selected from the group consisting of distearoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dimyristoylphosphatidylcholine,

Appln No.: 09/674,191

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

dilauroylphosphatidylcholine, dioleylphosphatidylcholine, hydrogenated egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and egg phosphatidylcholine.

18. (original) A pH-sensitive liposome in accordance with claim 13 wherein said lipid is a mixture of egg phosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

19. (original) A pH-sensitive liposome in accordance with claim 13 further comprising cholesterol

20. (original) A pH-sensitive liposome in accordance with claim 19 wherein said lipid is egg phosphatidylcholine.

21. (original) A pH-sensitive liposome in accordance with claim 13 further comprising a bilayer stabilizing component.

22. (previously presented) A pH-sensitive liposome in accordance with claim 13 wherein said bilayer stabilizing component is a member selected from the group consisting of lipids, lipid derivatives, detergents, proteins, peptides, polyethylene glycol and N-(.omega.-N'-acetoxy-octa(14'amino-3',6',9',12'-tetraoxatetradecanoyl)) (ATTA).

23. (original) A pH-sensitive liposome in accordance with claim 22 wherein said polyethylene glycol has a molecular weight ranging from about 200 to 10,000.

24. (original) A pH-sensitive liposome in accordance with claim 22 wherein said ATTA has a molecular weight ranging from about 200 to 10,000.

25. (original) A pH-sensitive liposome in accordance with claim 22 wherein said polyethylene glycol has a molecular weight ranging from about 2,000 to 6,000.

26. (original) A pH-sensitive liposome in accordance with claim 22 wherein said ATTA has a molecular weight ranging from about 2,000 to 6,000.

27. (original) A pH-sensitive liposome in accordance with claim 13 wherein said compound is present at a concentration ranging from about 1 weight percent to about 22 weight percent of said lipid

28. (original) A pH-sensitive liposome in accordance with claim 27 wherein said compound is present at a concentration ranging from about 2 percent to about 20 percent of lipid in a weight to weight ratio.

Appln No.: 09/674,191

Amendment Dated: July 13, 2005

Reply to Examiner's Amendment of June 3, 2005

29. (original) A pH-sensitive liposome in accordance with claim 27 wherein said compound is present at a concentration ranging from about 8 percent to about 10 percent of lipid.

30. (original) A pH-sensitive liposome in accordance with claim 19 wherein said cholesterol is present at a concentration ranging from about 0.02 mole percent to about 50 mole percent.

31. (original) A pH-sensitive liposome in accordance with claim 19 wherein said cholesterol is present at a concentration ranging from about 40 mole percent to about 45 mole percent.

32. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes permeable, unstable or fusogenic at a rate which can be controlled by pH

33. A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes destabilized at a rate which can be controlled by pH.

34. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes fusogenic at a rate which can be varied over a pH range of about 3 to about 10.


35. (original) A pH-sensitive liposome in accordance with claim 13 wherein said liposome becomes destabilized at a rate which can be controlled by varying Y

36. (original) A pH-sensitive liposome in accordance with claim 35 wherein Y is different in every other monomer n.

37. (original) A pH-sensitive liposome in accordance with claim 35 wherein Y is different in every other monomer i.

38. (previously presented) A method for delivering a therapeutic compound to a target cell comprising administering to a host containing said target cell a pH-sensitive liposome of claim 13, said pH-sensitive liposome comprising:
a lipid;
a compound of the formula

Appln No.: 09/674,191
 Amendment Dated: July 13, 2005
 Reply to Examiner's Amendment of June 3, 2005



39. (previously presented) A method in accordance with claim 38 further comprising a bilayer stabilizing component, wherein said bilayer stabilizing component is a member selected from the group consisting of lipids, lipid derivatives, detergents, proteins, peptides, polyethylene glycol and ATTA.

40. (original) A method in accordance with claim 38 wherein said liposome further comprises cholesterol.

41. (previously presented) A method in accordance with claim 38 wherein said liposome is fusogenic over a pH range from 4 to 7.

42. (original) A method in accordance with claim 38 wherein said liposome is administered intravenously.

43. (original) A method in accordance with claim 38 wherein said liposome is administered parenterally.

44. (original) A method in accordance with claim 38 wherein said liposome administered to said host is unilamellar.

45. (original) A method in accordance with claim 44 wherein said unilamellar liposome has a mean diameter of 0.05 microns to 0.45 microns.

46. (original) A method in accordance with claim 45 wherein said unilamellar liposome has a mean diameter of 0.05 microns to 0.2 microns.